# Trade Mark Journal No.2026/020 15 May 2026

## UK00004378376 24 April 2026 (5)

JOUVARI

International priority date claimed: 30 October 2025 (United States of America) (99471964)

Class 5
  Pharmaceutical preparations for treating alopecia, Alzheimer's disease, atopic dermatitis, autoimmune diseases, blood diseases, bone and skeletal diseases, cancer, cardiovascular diseases, sleep apnea, central nervous system diseases, cluster headaches, coronavirus disease, and Crohn's disease; Pharmaceutical preparations for treating dementia, dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders, fibromyalgia, gastrointestinal diseases and disorders, headaches, heart failure, inflammatory diseases and disorders, kidney diseases, liver diseases, lupus, and mental disorders; Pharmaceutical preparations for treating metabolic diseases and disorders, migraines, multiple sclerosis, neurodegenerative or neurological diseases and disorders, obesity, chronic weight management, osteoarthritis, pain, Parkinson's disease, psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and vascular diseases; Pharmaceutical preparations.

Amgen Inc.

Representative: Stevens Hewlett & Perkins